Deal Snapshot
VARIAN TO EXPAND PORTFOLIO WITH ACQUISITION OF EMBOLIC BEAD ASSET
Thursday 11 July 2019

US-based drug developer Varian (NYSE: VAR) has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors, the company said. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.
Varian's planned acquisition of the Boston Scientific portfolio of drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products will enable Varian to extend its new interventional oncology platform, and the company will benefit from the products' regulatory clearances in more than 35 countries worldwide.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 11/07/2019
Target: Boston Scientific/portfolio of drug-loadable microsphere and bland embolic bead products
Country: USA
Deal Size: 90m (USD)
Sector: Healthcare
Type: LBO
Financing: Cash
Status: Agreed
Vendor: Boston Scientific
Buyer: Varian
Comment:


Options